NeuOra Microceuticals has developed a revolutionary new micro, polymer hydrophilic matrix-based oral delivery system for nutraceuticals, probiotics and drugs. The unique features of the NeuOra delivery system are its size (140 mg), its ability to adhere to the gumline in the mouth, its slow rate of dissolve and its ability to deliver high-potency doses of bio-active agents in the mouth or, in the case of drugs, directly into the vascular system for rapid and sustained absorption.

The NeuOra tiny tablet adheres comfortably to the gumline. The tablet can be programmed to dissolve from a minimum of 30-minutes up to a maximum of 8 hours. By dissolving slowly in the mouth the NeuOra tablet maintains its bio-active potency compared to tablets that lose up to 80% potency through dissolution by gastric acids in the stomach and intestinal tract.

The development of the NeuOra bio-active delivery system was a 10-year collaboration between leading researchers in the science of sustained/continuous/time-release technologies including Douglas Pratt PhD., a University of California Berkeley-trained pharmacologist specializing in time-release delivery systems. The research and development was under the direction of Dr. Greggory R. DeVore (left), a world-renown, Yale University-educated physician and Clinical Professor, David Geffen School of Medicine at UCLA Los Angeles, California.


Neuora Microceuticals, LLC, a Salt Lake City, Utah-based company, was founded in 2013 to develop and private-label new nutraceutical products based on the NeuOra delivery system and license the NeuOra technology to the pharmaceutical industry for novel drug delivery. It products are manufactured in a state-of-the art FDA-monitored facility.

NeuOra Microceuticals is a privately held and financed company.

© NeuOra Microceuticals, 2013. All Rights Reserved.